9-<1'-(2'-Hydroxyethoxy)-3'-hydroxypropyl>adenine | 139342-70-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 9-<1'-(2'-Hydroxyethoxy)-3'-hydroxypropyl>adenine
• 英文别名: (3S)-3-(6-aminopurin-9-yl)-3-(2-hydroxyethoxy)propan-1-ol
• CAS: 139342-70-4
• 化学式: C₁₀H₁₅N₅O₃
• 分子量: 253.261
• InChiKey: HMDCTINWNWPBKB-ZETCQYMHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  119
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  9-(2-Deoxy-alpha-D-erythro-pentopyranosyl)-adenine 在 sodium tetrahydroborate 、 sodium periodate 作用下， 生成 9-<1'-(2'-Hydroxyethoxy)-3'-hydroxypropyl>adenine
  参考文献：
  名称：

  SnCl 4与TiCl 4介导的N-6-苯甲酰腺嘌呤与过苯甲酰化的2-脱氧吡喃糖之间的偶联：在某些同手性无环和碳环核苷酸的合成中的应用

  摘要：

  根据偶联剂SnCl 4或TiCl 4的性质，1,3,4-三-苯甲酰基2-脱氧核糖吡喃糖和被硅烷基化的N-6-苯甲酰腺嘌呤以两种不同的区域选择性方式反应。前一种路易斯酸产生N-9个核苷的异头混合物，而后者主要提供3'-脱氧3'-（N-6-苯甲酰基-9-腺苷基）糖基。这两个系列的衍生物构成用于制备同手性无环和碳环核苷酸的有用的合成子。

  DOI：

  10.1016/s0040-4020(01)96048-x

文献信息

• beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B
  申请人：Gosselin Gilles

  公开号：US20070087995A1

  公开（公告）日：2007-04-19

  This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2′-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2′-deoxy-β-L-erythro-pentofuranonucleoside has the formula: wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The 2′-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof may be administered either alone or in combination with another 2′-deoxy-β-L-erythro-pentofuranonucleoside or in combination with another anti-hepatitis B agent.

  本发明涉及一种治疗患有乙型肝炎的宿主的方法，包括给予有效量的抗HBV生物活性2'-脱氧-β-L-erythro-戊糖核苷或其药学上可接受的盐或前药，其中2'-脱氧-β-L-erythro-戊糖核苷的化学式为：其中R选自H，直链，支链或环烷基，CO-烷基，CO-芳基，CO-烷氧基烷基，CO-芳氧基烷基，CO-取代芳基，烷基磺酰基，芳基磺酰基，芳基烷基磺酰基，氨基酸残基，单磷酸、二磷酸或三磷酸，或磷酸衍生物；BASE是一种嘌呤或嘧啶碱基，可选择性地被取代。2'-脱氧-β-L-erythro-戊糖核苷或其药学上可接受的盐或前药可以单独或与另一种2'-脱氧-β-L-erythro-戊糖核苷或其他抗乙型肝炎药物联合使用。
• Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B
  申请人：Gosselin Gilles

  公开号：US20110195922A9

  公开（公告）日：2011-08-11

  This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2′-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2′-deoxy-β-L-erythro-pentofuranonucleoside has the formula: wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The 2′-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof may be administered either alone or in combination with another 2′-deoxy-β-L-erythro-pentofuranonucleoside or in combination with another anti-hepatitis B agent.

  本发明涉及一种治疗乙型肝炎感染宿主的方法，包括给予有效量的抗HBV生物活性2'-脱氧-β-L-核糖呋喃核苷或其药学上可接受的盐或前药，其中2'-脱氧-β-L-核糖呋喃核苷的化学式为：其中R选自羟基、直链、支链或环烷基、CO-烷基、CO-芳基、CO-烷氧基烷基、CO-芳氧基烷基、CO-取代芳基、烷基磺酰基、芳基磺酰基、芳基烷基磺酰基、氨基酸残基、单、双或三磷酸盐或磷酸衍生物；BASE为嘌呤或嘧啶碱基，其可以选择性地被取代。2'-脱氧-β-L-核糖呋喃核苷或其药学上可接受的盐或前药可以单独或与另一种2'-脱氧-β-L-核糖呋喃核苷或另一种抗乙型肝炎药物联合给药。
• US7304043B2
  申请人：——

  公开号：US7304043B2

  公开（公告）日：2007-12-04